All-trans retinoic acid-incorporated nanoparticles of deoxycholic acid-conjugated dextran for treatment of CT26 colorectal carcinoma cells
Authors Jeong Y, Chung K, Kim DH, Kim Y, Lee YS, Choi K
Received 21 November 2012
Accepted for publication 28 December 2012
Published 30 January 2013 Volume 2013:8(1) Pages 485—493
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Young Il Jeong,1,* Kyu Don Chung,2,* Da Hye Kim,3 Yoon Hyuk Kim,4 Yeon Soo Lee,5 Ki Choon Choi3
1Cancer Center, Chonnam National University Hwasun Hospital, Hwasun, South Korea; 2Department of Anesthesiology and Pain Medicine, Catholic University, Seoul, South Korea; 3Grassland and Forage Research Center, Rural Development Administration, Cheonan, South Korea; 4Department of Mechanical Engineering, Kyung Hee University, Seoul, South Korea; 5Department of Biomedical Engineering, Catholic University of Daegu, Daegu, South Korea
*These authors equally contributed to this work
Purpose: All-trans retinoic acid (RA)-incorporated nanoparticles were prepared using deoxycholic acid-conjugated dextran (DexDA). Anticancer activity of RA-incorporated DexDA nanoparticles were tested in vitro and in vivo.
Methods: RA-incorporated nanoparticles were prepared by dialysis. Antiproliferative and anti-invasive potential of RA-incorporated nanoparticles were studied using CT26 colorectal carcinoma cells.
Results: RA-incorporated nanoparticles have small particle sizes of around 70–300 nm and spherical shapes. The higher drug-feeding ratio and higher substitution degree of deoxycholic acid in the conjugates resulted in higher drug contents, lower loading efficiency, and larger particle size. RA release rate became slower at higher drug contents and higher substitution degree of deoxycholic acid in the DexDA conjugates. The antiproliferation activity, anti-invasive activity, and matrix metalloproteinase 2 expression of RA-incorporated nanoparticles against CT26 cells in vitro was similar to RA. However, RA-incorporated nanoparticles had superior antimetastatic activity in an animal pulmonary metastatic model of CT26 cells compared to RA itself.
Conclusion: RA-incorporated nanoparticles showed similar anticancer activity in vitro and superior antimetastatic activity in vivo in a pulmonary metastatic model of CT26 cells. We suggest that RA-incorporated nanoparticles are promising vehicles for efficient delivery of RA.
Keywords: nanoparticle, dextran, deoxycholic acid, retinoic acid, cancer cell invasion
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]